Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States: 

Non-Small Cell Lung Cancer (adenocarcinoma)

Intended Audience: Oncologists, Pulmonologists, Surgeons, Pathologists, Community HCPs; Patients/Caregivers

Bayer TA Rationale for Educational Support:

Areas of interest based on referenced literature: 

• Treatment and management of non-small cell lung cancer (adenocarcinoma)
• Treatment and management of non-small cell lung cancer (adenocarcinoma)
• Education on biomarker driven testing strategies/appropriate testing modalities
• Role of TRK-fusion and impact of TRK-fusion testing in non-small lung cancer (adenocarcinoma) treatment algorithms
• Implication of TRK pathway aberrations in the pathogenesis of cancer
• Treatment and management of TRK fusion cancers
• Understanding of efficacy and safety profiles of approved TRK inhibitors
• How to Prioritize Treatment
• Multi-disciplinary approach to precision medicine
• Importance of precision medicine in community regional settings

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget 

Provider Justification: 

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic areas

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References 

Management and treatment of metastatic CRC

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2019 – August 30, 2019 (Link)

2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.2020 – October 10, 2019 (Link)

   Diagnosis, treatment and management of TRK fusion cancer 

3. Hong DS, Bauer TM, Lee JJ et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1;30(2):325-331. (Link)
4. Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family protein in cancer. Pharmacol Ther 2017 (173), 58-66. (Link)
5. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (Link)
6. Cocco, E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (Link)
7. Hyman, DM et al. Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer. Annals of Oncology 30 (5), October 2019 (Link)
8. Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (Link)
9. Ricciuti, B et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019 Apr 30;12:3171-3179 (Link)
10. Halliday, PR et al. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019 Feb 26;21(3):21. (Link)
11. Solomon, JP et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019 Aug 2. (Epub ahead of print) (Link)
12. Wong, D et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019 Jun 29. (Epub ahead of print) (Link)
13. Lin, J. et al. Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer. ASCO 2021 Presentation.
14. Drilon, Alexander et al. “Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.” JCO precision oncology vol. 6 (2022): e2100418. doi:10.1200/PO.21.00418 (Link)
15. M. Hoejgaard wt al,.Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib . Journal of Thoracic Oncology (2023) 18 (4S): S35-S88. (Link)
16. JJ Lin et al., Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Journal of Clinical Oncology Volume 41, Number 16_suppl. 2023 (Link)